Part II — The Evidence Annex

Every exhibit, in the order Part I presents it. Each sits on its own page. The original document is reproduced wherever this machine holds it as a file; OCR is reproduced and labelled as OCR wherever only OCR exists; and where the document is named but not held, the page says NOT HELD and gives the evidence that it exists.

E-01 · 16 July 2016 · Coroner's Investigation Statement (Form 3)

Document: CIS Case No. 2016-8196, Statement No. 2016-1034-B, coroner 20174 Dr. Bishwajit Bora. **Held as:** verbatim transcription in `NODE-01-JULY-2016/TRANSCRIPT-coroner-package-16pp.md`, package pages 2–3. Page photographs are not on this machine; the transcription is stated to be a transcription. **Status:** OCR/transcription only. Primary images not readable by this session.

> "Name: Ceylan, Raffi · Gender: Male · Date of Birth: 05/Feb/1973 · Age: 43 yrs"
>
> "Death Pronounced: 16/Jul/2016 By what means: Natural Death Municipality: CHAPLEAU · Address: Island Lake RD · City: CHAPLEAU Environment: Motor Vehicle - Passenger Death Factor: Natural Disease - Cardiovascular - Other"
>
> "Medical cause of death: Probable Primary Cardiac Arrhythmia" "Due to / as a consequence of:" — empty "Contributing Factors:" — empty
>
> "The girlfriend yelled for help and a friend attended in the RV. 911 was called and cardiopulmonary resuscitation was commenced."
>
> "He had blanching lividity and partial rigor mortis. A bruise was noted over the left eyelid."

Establishes: time and place of death; the group of twelve; that EMS attended and resuscitation was attempted; the recorded cause and manner; that the friend and the girlfriend are unnamed; that the coroner's signature and date fields on the form are empty. **Does not establish:** who the friend was; the EMS record; any conclusion about the bruise.

E-02 · 19 July – 7 November 2016 · Final Autopsy Report 16:SA198

Document: Final Autopsy Report, Northeastern Regional Forensic Pathology Unit, Health Sciences North, Sudbury. Examination commenced 19 July 2016, 13:30. Electronically signed MARTIN QUEEN MD FRCP(C) **07/11/16** — 7 November 2016. **Held as:** transcription, `NODE-01-JULY-2016/TRANSCRIPT-coroner-package-16pp.md`, package pp.1–5, 8. **Status:** OCR/transcription only.

> "on the 19th day of July, 2016 about 45 hours after death pronounced"
>
> "Temperature: Cold Rigor Mortis: present Postmortem Lividity: Posterior surface of body, fixed Decomposition: Nil"
>
> "NO ANATOMICAL or TOXICOLOGICAL CAUSE of DEATH Consistent with CARDIAC ARRHYTHMIA"
>
> "EMS was dispatched to the scene and attempted resuscitation in the RV and then in the ambulance. His wife reported that he had no significant medical history"

Establishes: the interval printed on the report's face; the state of the body as recorded at autopsy; the cause-of-death finding in the report's own words; the signature date. **Arithmetic on the record's own numbers:** pronounced 16 July 16:33 → examined 19 July 13:30 = **68 h 57 min**, against the "about 45 hours" on the same page. **Does not establish:** why the interval differs; why rigor reads "partial" at the scene and at the unit and "present" in the report.

E-03 · 28–29 July 2016 · CFS toxicology summary and evidence list

Document: CFS Toxicology Coroner's Case Analytical Summary, CFS File 2016-001036, 28 July 2016; CFS Evidence List Report, printed 29 July 2016, four items, all processed 19 July. **Held as:** transcription, package pp.6–7; OCR `lucy_ocr_out/`. **Status:** OCR/transcription only.

> Evidence List: four items submitted. Results returned for two; the remainder, in the record's own words, **"have not been tested"**.

Establishes: what was submitted and what was not tested. **Does not establish:** the values for the untested items, or why they were left untested.

E-04 · 23 August 2016 · Vitreous chemistry record

Document: vitreous chemistry electronic record, run date 23/08/16. **Held as:** transcription (package p.8); OCR. **Status:** the values are **not legible** in the copy held.


Establishes: that the test was run, five weeks after death. **Does not establish:** any value in it.

E-05 · 14 October 2016 · GeneDx Cardiology Genetics Report

Document: GeneDx accession 1638665, six pages, faxed 14 October 2016 at 11:09:55 EDT. **Held as: the document itself** — `NODE-01-JULY-2016/evidence/16SA198-CEYLAN-Raffi-MQ-GeneDx-6pp.pdf`. The six pages follow this page in this annex.

> ANK2 variant classified **"Variant of Uncertain Significance"**; the report states the result **"cannot be interpreted for diagnosis."**

Establishes: the classification, in the laboratory's own words. **Does not establish:** any causal link between the variant and the death. The report itself refuses that reading.



** INBOUND NOTIFICATION : FAX RECEIVED SUCCESSFULLY **

TIME RECEIVED	REMOTE CSID	DURATION	PAGES	STATUS
14 October, 2016 11:09:55 AM EDT	Fax Server	238	6	Received

Fax Server 10/14/2016 11:08:01 AM PAGE 1/006 Fax Server

GeneDx
207 Perry Parkway
Gaithersburg, MD 20877
Phone: 301-519-2100
Fax: 201-421-2010
E-mail: genedx@genedx.com
Website: www.genedx.com

Fax

GeneDx Accession Number: 1638665

To: Dr. Kris Cunningham **From:** Clinical Staff

Forensic Services Technologist

Fax: 416-314-4060 **Pages:** 6

TEST	Comprehensive Arrhythmia Panel			
FAXED	14-OCT-2016			

GeneDx is going green! As part of our effort to be environmentally responsible, beginning 1/1/2014, GeneDx will no longer send genetic test reports by mail. We will continue to send reports by fax, email or through our electronic reporting system according to your preferences.

If you are interested in an electronic method of report delivery, GeneDx utilizes the CareEvolve reporting system. CareEvolve is a user-friendly, web-based, HIPAA compliant, secure report retrieval system. This method allows for quick electronic access to reports that will help eliminate excess paper copies. Reports are uploaded every hour in a convenient pdf format and can be accessed and retrieved repeatedly.

If you are interested in learning more about the CareEvolve system, please contact our Customer Service Specialist at techsupport@genedx.com.

Thank you,
GeneDx Clinical Staff

Additional tests can be added on most specimens if we receive faxed orders including authorization FROM THE PARTY TO BE BILLED. Physicians, please route your requests through the in-house or local laboratory that handled the initial specimen.

The information contained in this message may be privileged and confidential medical information intended solely for the addressee(s). If you are not the intended recipient, please notify the sender immediately and destroy this message and its attachments. Do not read, disclose, retain or copy the contents.

GeneDx report, page 1 of 6 — original document, from 16SA198-CEYLAN-Raffi-MQ-GeneDx-6pp.pdf

Cardiology Genetics Report

Patient Name:	**CEYLAN, Raffi**	**GeneDx Accession No:**	**1638665**
Date of Birth:	**05-FEB-1973**	**Date Specimen Obtained:**	**16-JUL-2016**
Specimen Type:	**DNA**	**Date Specimen Received:**	**16-SEP-2016**
Submitters ID No:	**16SA198 MQ, 2v80861**	**Date Test(s) Started:**	**16-SEP-2016**
Ordered By:	**Dr. Kris Cunningham**	**Date of Report:**	**14-OCT-2016**

Test(s) Requested: Comprehensive Arrhythmia Sequencing and Deletion/Duplication Panel

Genes Evaluated: ABCC9, AKAP9, ANK2, CACNA1C, CACNA2D1, CACNB2, CALM1, CALM2, CALM3, CASQ2, CAV3, DES, DSC2, DSG2, DSP, GPD1L, HCN4, JUP, KCND3, KCNE1, KCNE2, KCNE3, KCNE1L, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, LMNA, NKX2.5, PKP2, PLN, RANGRF, RYR2, SCN10A, SCN1B, SCN2B, SCN3B, SCN4B, SCN5A, SNTA1, TGFB3, TMEM43, TRDN, TRPM4, TTN

Result: **SEE INTERPRETATION**

Gene	Coding DNA	Variant	Zygosity	Classification
ANK2	c.3718 C>G	p.Pro1240Ala (P1240A)	Heterozygous	Variant of Uncertain Significance

No definitive pathogenic variants known to be associated with arrhythmia were identified by sequence analysis of the 46 genes on this panel. No deletion or duplication involving any of the 45 genes analyzed was found by concurrent targeted array CGH (ExonArrayDx). The CALM1 gene is not included on the Arrhythmia ExonArrayDx.

Interpretation: **This individual is heterozygous for variant of uncertain significance in the ANK2 gene.**

The Comprehensive Arrhythmia Panel includes sequence and deletion/duplication analysis of genes that cause various arrhythmia syndromes. Many of these genes code for ion channel proteins of the heart muscle that mediate the movement of sodium, potassium and calcium ions in and out of cardiac cells, as well as their associated regulatory factors and interaction partners. There are several different genetic arrhythmia disorders. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) affects the cardiac desmosome, which is a protein complex that maintains cell-to-cell connections and provides mechanical attachments between adjacent cells. ARVC is characterized by myocyte death and replacement by fat and fibrous tissue in the right ventricle, predisposing to ventricular tachyarrhythmia and sudden cardiac death (McNally et al., 2014; Nava et al., 2000). Brugada syndrome (BrS) is caused by abnormal ion channel function and is characterized by ST segment elevation on ECG (leads V1-3) in the absence of structural heart disease. BrS is associated with increased risk for syncope, ventricular tachyarrhythmia and sudden cardiac death (Fowler et al., 2009; Hedley et al., 2009; Brugada et al., 2014). Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by cardiac calcium channel dysfunction that is precipitated by stress-induced release of catecholamines (de la Fuente et al., 2008; Priori et al., 2002). Long QT syndrome (LQTS) is characterized by prolongation of the QT interval on ECG and is associated with increased risk for syncope, ventricular arrhythmia, and sudden cardiac death in individuals with normal heart structure (Goldenberg et al., 2008; Priori et al., 2004; Alders and Christiaans, 2015; Tranebjaerg et al., 2014). Genetic predisposition to a cardiac arrhythmia may occur as an isolated feature or may be part of a multisystemic disorder, such as Jervell and Lange-Nielsen syndrome, Timothy syndrome, Andersen-Tawil syndrome, Naxos disease, Carvajal syndrome and muscular dystrophy.

ANK2 Summary: The ANK2 gene is a member of the ankyrin protein family, which play a role in cell motility, activation, proliferation, contact, and maintenance of specialized membrane domains (MIM: 106410). Heterozygous pathogenic variants in ANK2 have been reported in association with Long QT syndrome (LQTS) (Mohler et al., 2003).

GeneDx DNA DIAGNOSTIC EXPERTS

Cardiology Genetics Report

Patient Name:	**CEYLAN, Raffi**	**GeneDx Accession No:**	**1638665**
Date of Birth:	**05-FEB-1973**	**Date Specimen Obtained:**	**16-JUL-2016**
Specimen Type:	**DNA**	**Date Specimen Received:**	**16-SEP-2016**
Submitters ID No:	**16SA198 MQ, 2v80861**	**Date Test(s) Started:**	**16-SEP-2016**
Ordered By:	**Dr. Kris Cunningham**	**Date of Report:**	**14-OCT-2016**

ANK2 p.P1240A: p.Pro1240Ala (P1240A) (CCC>GCC): c.3718 C>G in exon 31 of the ANK2 gene (NM_001148.4)

A variant of uncertain significance has been identified in the ANK2 gene. The P1240A variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. This variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The P1240A variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species and in silico analysis predicts this variant is probably damaging to the protein structure/function. However, to our knowledge no studies have been performed to determine the functional effect of the P1240A variant.

Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign. This result cannot be interpreted for diagnosis or used for family member screening at this time.

Recommendation:

1. It is recommended that any first-degree relatives receive continued clinical evaluation and follow-up.

2. Targeted testing of affected relatives could be considered to determine if the P1240A variant in the ANK2 gene segregates with disease in this family. If there are no affected relatives, targeted testing of this individual's parents could be considered to determine if the variant occurred de novo. Cumulative data about this variant, including multiple instances of segregation with disease and/or de novo occurrence may assist in further variant interpretation and classification.

3. Genetic counseling is recommended to discuss the implications of this test report, specifically the risk of recurrence for this family.

Resources: Patients willing to share their genetic and health data (de-identified for privacy) to advance knowledge and to connect with others with the same variant/condition can visit genomeconnect.org.

Methods: Using genomic DNA from the submitted specimen, the coding regions and splice junctions of the 46 genes (Only exons 1-44 for CACNA1C, only the KCNQ1-binding domains including Ser1570 residue for AKAP9, and excluding exon 6 of the PKP2 gene and the following genomic regions of the TTN gene: chr2:179527692-179527782, 179523898-179523982, 179523731-179523815) are enriched using a proprietary targeted capture system developed by GeneDx. These targeted regions are sequenced simultaneously by massively parallel (NextGen) sequencing on an Illumina platform with paired-end reads. Bi-directional sequence is assembled, aligned to reference gene sequences based on human genome build GRCh37/UCSC hg19, and analyzed for sequence variants. Capillary sequencing is used to confirm all potentially pathogenic variants and to obtain sequence for regions where fewer than 15 reads are achieved by NextGen sequencing. Concurrent deletion/duplication testing was performed using exon-level oligo array CGH (ExonArrayDx) for most of the coding exons of the requested genes, except for CALM1. KCNE1L and SCN1B have gene level resolution; exon level events may not be detected. Data analysis is performed using gene-specific filtering. Probe sequences and locations are based on human genome build GRCh37/UCSC hg19. The array is designed to detect most intragenic deletions and duplications. Confirmation of copy number changes is performed by MLPA, qPCR, or repeat array CGH analysis. Sequence and array CGH alterations are reported according to the Human Genome Variation Society (HGVS) or International System for Human Cytogenetic Nomenclature (ISCN) guidelines, respectively. Benign and likely benign variants, if present, are not included in this report but are available upon request.

GeneDx
GENE DIAGNOSTIC EXPERTS

Cardiology Genetics Report

Patient Name:	**CEYLAN, Raffi**	**GeneDx Accession No:**	**1638665**
Date of Birth:	**05-FEB-1973**	**Date Specimen Obtained:**	**16-JUL-2016**
Specimen Type:	**DNA**	**Date Specimen Received:**	**16-SEP-2016**
Submitters ID No:	**16SA198 MQ, 2v80861**	**Date Test(s) Started:**	**16-SEP-2016**
Ordered By:	**Dr. Kris Cunningham**	**Date of Report:**	**14-OCT-2016**

Supplemental Variant Information:

Gene: Coding DNA	**ANK2: c.3718 C>G**
Variant (Protein)	p.Pro1240Ala (P1240A)
Classification	Variant of Uncertain Significance
Zygosity	Heterozygous
Chr: Position	4: 114257859
dbSNP	
1000G	
1000G_Highest	
1000G_Highest_Sub	
ExAC_Freq	
ExAC_Latino	
ExAC_NFE	
ExAC_AFR	
ExAC_EAS	
ExAC_FIN	
ExAC_Other	
ExAC_SAS	
ExAC_Hom	
PROVEAN	
MutTaster_Score	1 (D)
Interpro_Domain	
ClinVar	

GeneDx DNA DIAGNOSTIC EXPERTS

Cardiology Genetics Report

Patient Name:	**CEYLAN, Raffi**	**GeneDx Accession No:**	**1638665**
Date of Birth:	**05-FEB-1973**	**Date Specimen Obtained:**	**16-JUL-2016**
Specimen Type:	**DNA**	**Date Specimen Received:**	**16-SEP-2016**
Submitters ID No:	**16SA198 MQ, 2v80861**	**Date Test(s) Started:**	**16-SEP-2016**
Ordered By:	**Dr. Kris Cunningham**	**Date of Report:**	**14-OCT-2016**

This supplement provides evidence to support the classification of each reportable variant in the attached result report. This information is provided as a resource and may not be inclusive of all available information used by GeneDx for variant classification. The variant classification does not rely solely on any one of the individual criterion provided below. In addition, each criterion is weighted differently to derive the classification. This information is subject to change over time and may differ from what is currently available. This supplement is provided upon request to ordering providers. GeneDx has already conducted a thorough analysis of the data at the time testing was ordered and does not provide additional support to providers who have questions about the tools used in variant analysis and interpretation for a specific case. Results should always be interpreted in the context of the patient's clinical presentation.

Blank fields indicate that no data was available at time of analysis.

Data from the 1000 Genomes Project has been modified by GeneDx to exclude related individuals. For more information about the specific populations included in the 1000 Genomes Project, please see http://www.1000genomes.org (McVean et al., 2012).

The Exome Aggregation Consortium (ExAC) provides a beta-version of a set of exome sequencing data from a variety of large-scale sequencing projects (Lek et al., 2016). The ExAC set includes data from individuals who were recruited for disease-specific studies, including cancer and cardiovascular diseases. Genotype quality metrics and site quality metrics for a specific variant are available at http://exac.broadinstitute.org.

REFERENCES:
1. 1000 Genomes Project: McVean et al. (2012) Nature 491 (7422):56-65 (PMID: 23128226). 2. ExAC: Lek et al. (2016) Nature 536 (7616):285-91 (PMID: 27535533). 3. PROVEAN: Choi et al. (2012) PLoS ONE 7 (10):e46688 (PMID: 23056605). 4. Mutation Taster: Schwarz et al. (2014) Nature methods 11 (4):361-2 (PMID: 24681721). 5. CADD: Kircher et al. (2014) Nature Genetics 46 (3):310-5 (PMID: 24487276). 6. Interpro: Mitchell et al. (2015) Nucleic Acids Res. 43 (Database issue):D213-21 (PMID: 25428371). 7. ClinVar: Landrum et al. (2014) Nucleic Acids Res. 42 (1):D980-5 (PMID: 24234437).

Frequency/Catalog Information

dbSNP - NCBI repository for single base nucleotide substitutions and short deletion and insertion polymorphisms

1000G - Variant allele frequency among 2500 individuals included in the 1000 Genomes project, a catalog of human genetic sequence variation obtained through genomic sequencing (Percent values in parentheses)

1000G_Highest - Highest reported percentage frequency of a variant in any 1000G sub-population

1000G_Highest_Sub - Sub-population referenced in 1000G_Highest (AMR=Admixed American, EAS=East Asian, SAS=South Asian, AFR=African, EUR=European)

ExAC_Freq - Variant allele frequency among approximately 60,000 individuals included in the Exome Aggregation Consortium (ExAC) dataset, a catalog of human genetic sequence variation obtained through exome sequencing (Percent values in parentheses)

ExAC_Latino - ExAC variant frequency (in percent) for individuals of Latino ancestry

ExAC_NFE - ExAC variant frequency (in percent) for non-Finnish individuals of European ancestry

ExAC_AFR - ExAC variant frequency (in percent) for individuals of African ancestry

ExAC_EAS - ExAC variant frequency (in percent) for individuals of East Asian ancestry

ExAC_FIN - ExAC variant frequency (in percent) for Finnish individuals of European ancestry

ExAC_Other - ExAC variant frequency (in percent) for individuals of other ancestry

ExAC_SAS - ExAC variant frequency (in percent) for individuals of South Asian ancestry

ExAC_Hom - The number of individuals in ExAC who are homozygous for the variant

Information on Prediction Scores

PROVEAN (Protein Variation Effect Analyzer) - predicts whether an amino acid substitution or indel affects the biological function of a protein using a delta alignment score from -14 to +14 (more negative=more damaging) with a predefined threshold of -2.5. If the PROVEAN score is equal to or below -2.5, the variant is predicted to have a deleterious effect. If the PROVEAN score is greater than -2.5, the variant is predicted to have a neutral effect.

MutTaster_Score - Represents the strength of the calculation matching a simple, automated prediction based on population statistics and ClinVar data (Example: A high-scoring variant may be both calculated to be damaging and has a 'damaging' flag in ClinVar.) A high score does NOT indicate a high probability of accuracy. Predictions (in parentheses) are: 'A' - Disease-causing Automatic (known pathogenic), 'D' - Disease-causing, 'N' - Polymorphism, 'P' - Polymorphism Automatic (known benign).

Note that the in silico scores used by GeneDx are precomputed and may change over time. In silico models use algorithms that predict the effect a variant may have on the protein, but they do not provide direct evidence regarding the actual impact on protein structure or function. In silico models should be interpreted with caution and only be used in combination with other available evidence to support the classification of any variant. CADD (Combined Annotation Dependent Depletion) is also used by GeneDx to evaluate the deleterious effect of a single nucleotide variant (SNV) or indel.

Interpro_Domain - Domain annotations come from the Interpro database. The number in parentheses reflects how many times Interpro has assigned the variant position to that domain, typically derived from different predicting databases.

ClinVar - Classification of variant in ClinVar database, an NCBI archive of human variants with supporting evidence of phenotypic association.

GeneDx DNA DIAGNOSTIC EXPERTS

Cardiology Genetics Report

Patient Name:	**CEYLAN, Raffi**	**GeneDx Accession No:**	**1638665**
Date of Birth:	**05-FEB-1973**	**Date Specimen Obtained:**	**16-JUL-2016**
Specimen Type:	**DNA**	**Date Specimen Received:**	**16-SEP-2016**
Submitters ID No:	**16SA198 MQ, 2v80861**	**Date Test(s) Started:**	**16-SEP-2016**
Ordered By:	**Dr. Kris Cunningham**	**Date of Report:**	**14-OCT-2016**

Report electronically signed by:
Hong Cui PhD, DABMG
Assistant Director, Mitochondrial Disorders

Report electronically signed by:
Mitzi Murray MD, MA, FACMG
Assistant Director, Cardiogenetics Program

References: McNally E, MacLeod H, Dellefave-Castillo L. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. 2005 Apr 18 [Updated 2014 Jan 9]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1131/

Nava et al. (2000) Journal of the American College of Cardiology 36 (7):2226-33 (PMID: 11127465)

Fowler et al. (2009) Current Opinion In Cardiology 24 (1):74-81 (PMID: 19102039)

Hedley et al. (2009) Human mutation 30 (9):1256-66 (PMID: 19606473)

Brugada, Campuzano, Brugada, et al. Brugada Syndrome. 2005 Mar 31 [Updated 2014 Apr 10]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1517/

de la Fuente et al. (2008) Pacing And Clinical Electrophysiology : Pace 31 (7):916-9 (PMID: 18684293)

Priori et al. (2002) Circulation 106 (1):69-74 (PMID: 12093772)

Goldenberg et al. (2008) Current problems in cardiology 33 (11):629-94 (PMID: 18835466)

Priori et al. (2004) Annals of the New York Academy of Sciences 1015:96-110 (PMID: 15201152)

Alders M, Christiaans I. Long QT Syndrome. 2003 Feb 20 [Updated 2015 Jan 18]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1129/

Tranebjaerg L, Samson RA, Green GE. Jervell and Lange-Nielsen Syndrome. 2002 Jul 29 [Updated 2014 Nov 20]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1405/

Online Mendelian Inheritance in Man, OMIM. Johns Hopkins University, Baltimore, MD. MIM Number: {MIM 106410}: {8/20/2010 edited}: World Wide Web URL: http://omim.org/

Mohler et al. (2003) Nature 421 (6923):634-9 (PMID: 12571597)

Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [9/2016 accessed]

Limitations: Genetic testing using the methods applied at GeneDx is expected to be highly accurate. Normal findings do not rule out the diagnosis of a genetic disorder since some genetic abnormalities may be undetectable with this test. Neither sequencing nor exon-level array CGH can reliably detect mosaicism and/or chromosomal aberrations. Deletions/insertions of 5 bp or more are not reliably detected by the NextGen sequencing methodology and deletions/insertions of less than 500 bp are not reliably detected by array CGH. Rarely incidental findings of large chromosomal rearrangements (>3Mb) outside the gene of interest may be identified. Some genes have inherent sequence properties (for example: repeat, homology, or pseudogene regions, high GC content, rare polymorphisms) that may result in suboptimal data, and variants in those regions may not be reliably identified. False negative results may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. The chance of a false positive or false negative result due to laboratory errors incurred during any phase of testing cannot be completely excluded. Interpretations are made with the assumption that any information provided on family relationships is accurate. Consultation with a genetics professional is recommended for interpretation of results.

Disclaimer: This test was developed and its performance characteristics determined by GeneDx. It has not been cleared or approved by the U.S. Food and Drug Administration. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

E-06 · undated · Regional Supervising Coroner's email to the widow

Document: email of David A. Cameron, MD, LLB, CCFP, Regional Supervising Coroner, North Region, Sudbury — subject "FW: EXT: RE: 16SA198 CEYLAN, R DNA Results" — attaching "CEYLAN, Raffi PM Report.pdf" and "CEYLAN, Raffi Tox.pdf". **Held as:** transcription (package, gallery `20260106_144108.jpg`). **Status:** OCR/transcription only.

> "Cause of Death: No anatomic or toxicologic cause of death consistent with cardiac arrhythmia" "This means that no abnormalities were found and so a cardiac arrhythmia is the most likely cause. The cardiac gene testing done in the U.S. shows a 'variant of uncertain significance in the ANK2 gene.'"

Establishes: that the coroner's office read the absence of findings as the finding. **Does not establish:** the reasoning behind that step. No document in the corpus sets it out.

E-07 · 10 May 2019 · Release of the coroner's package

Document: cover letter, Office of the Chief Coroner, Sudbury, Emily Groot MD, to Ms. Lucy Ceylan; 16-page package; released under s.18(7) of the Coroners Act. **Held as:** transcription (package p.1). **Status:** OCR/transcription only. Addressed to Raffi's sister, not to the estate trustee.

Establishes: that the family obtained the death-investigation record directly, three years after the death.

E-08 · 6 November 2026 · Corporate Profile Report, NORTHERN EXPOSURE DECKS & FENCES LTD.

Document: Ontario Ministry of Public and Business Service Delivery Profile Report, as of 31 December 2016, Transaction APP-A11300127133, 8 pages, certified "a true copy of the record", generated 6 November 2026 08:27. **Held as:** document + verbatim transcription, `NODE-02-SEPT-OCT-2016/PROFILE-REPORT-2003951.txt`. **Status:** produced and read in full.

> "Name: NORTHERN EXPOSURE DECKS & FENCES LTD. · Ontario Corporation Number (OCN): 2003951 · Status: Active · Date of Incorporation: June 28, 2001"
>
> "Minimum Number of Directors: 1 / Maximum Number of Directors: 7" "Active Director(s) — Name: IVANA HRVATIN · Resident Canadian: Yes · Date Began: September 30, 2016" "Active Officer(s) — IVANA HRVATIN · Position: President · Date Began: September 30, 2016" "IVANA HRVATIN · Position: Secretary · Date Began: September 30, 2016"

Document List, thirteen filings: twelve read **PAF: RAFFI CEYLAN — OFFICER / DIRECTOR**, from the Initial Return of 20 July 2001 (OCR prints "July 20, 2001"; the list's own line date) through Annual Return 2013.

Establishes: fifteen years of one filing authority; one person holding every office from 30 September 2016. **Does not establish:** when Raffi ceased to be a director (no former-director field); any share position (no share field in the eight pages).

E-09 · 30 September 2016 · The Notice of Change

Document: line 1 of the same Document List.

> "CIA - Notice of Change PAF: BARTON J. SEGUIN - OTHER Effective Date: September 30, 2016"

Held as: the Profile Report above. **Status:** produced. **The instrument behind it — resolution, consent, signature — is NOT HELD anywhere in this corpus.**

Establishes: that the registry records a person classified as holding no office as the person who authorized the change of directors and officers, effective 30 September 2016. **Does not establish:** who signed what, on what date, on whose authority.

E-10 · faxed 14 September 2016 · Sun Life transfer-of-ownership form

Document: the instrument that would connect policy to deposit. **Status: NOT HELD in unredacted form.** A redacted copy exists in Frank's own set; the Longo affidavit records that Potvin undertook to produce the form unredacted and did not [BC ¶H.4].

Establishes: only the fax stamp date, 2016/09/14. **Does not establish:** the policy number, the designation, the signature, the signer, or the date signed. This is the single largest gap in the chain.

E-11 · statement period ending 30 November 2016 · TD business chequing statement

Document: TD Canada Trust BUSINESS CHEQUING, NORTHERN EXPOSURE DECKS & FENCES LTD., account `0084 7411-5001963`. Two copies read (`1000088787`, `1000087951` / `image009`). **Status:** OCR of the image; the primary image is `muse:muse 660` and is not openable by this session.

```
BALANCE FORWARD   SEP30   11,248.27 (overdrawn)
NSF               432.00  OCT04   10,816.27
UNION GAS LTD BPY  51.75  OCT18   10,868.02
DEPOSIT                           10,686.32 -> balance column
charges: 5.00 + 2.00 + 25.00 + 68.60 = 100.60
closing balance printed            596,441.78
check: 607,228.70 - 10,686.32 - 100.60 = 596,441.78   EXACT
```

> deposit line: "607,228.70" · monthly average credit balance **$19,240** · "NEXT STATEMENT DATE IS NOV 30/16"
>
> Copy B line 74: "$11,248.27OD **607,842.40**"

Establishes: the sum entered the corporation's business account; the account was overdrawn by $10,686.32 immediately before; the balance after the deposit was $596,441.78; the money left within the period (average balance $19,240). **Does not establish:** the deposit date printed on the statement; where the money went; what 607,842.40 is. That figure is used in no arithmetic in this package.

E-12 · 16 November 2016 · The sheet Seguin handed over

Document: two-page "LIST OF ESTATE ASSETS/DEBTS", personal (p.1) and corporate (p.2), `1000082583.jpg.txt`. Handwritten heading: "Sheet that was provided [by] Bart Seguin to my mother and [Julie] during their meeting with him on Nov[ember 16, 2016]". **Status:** OCR only.

line	item	figure as printed
25	Residence (50%), 4967 4th Conc.	195,000.00 "Re value"
33	block subtotal (insurance proceeds / RRSP / non-registered / TFSA, Empire Life)	349,468.93
63	TOTAL ESTIMATED PERSONAL [OCR damaged]	**167,488.09**
69	Business: equipment / tools / dump truck	20,000.00 approx.
70	Receivables to bank	14,978.15 collected and deposited
71–75	INSURANCE PROCEEDS SUN LIFE	lines damaged; total **634,978.15** received
78	OVERDRAFT TO BANK ACCT NO. 7411-5001963	25,664.47 "paid out of funds received"
84	Business liabilities subtotal	35,289.86
95	TOTAL ESTIMATED BUSINESS ESTATE ASSETS [OCR damaged]	167,176.38

Four of the printed totals are legible; the lines that compose them are not, so no computed total is carried out of this sheet anywhere in this package. Note that the 349,468.93 block and the 167,488.09 personal total cannot both be the personal estate, and the record does not say which lines sit inside which.

Establishes: the estate's lawyer's own figure for the insurance proceeds, and the family's net position as of the first weeks after the death. **Does not establish:** how 634,978.15 decomposes (component lines damaged in OCR); why it is $27,749.45 above the bank deposit.

E-13 · 16 November 2016 · Transcript of the meeting in Seguin's office (fragment)

Document: `1000087932.jpg.txt`, transcript lines covering 19:38–32:10 of the recording, with the family's handwritten annotation layered on the page. Quote below is transcript only; annotations are the family's and are excluded. **Status:** OCR of an annotated fragment. **The audio is NOT HELD** — attested by its maker, described in the affidavit as Exhibit 19 in Lucy Ceylan's possession.

> "@19:38 — Mom 'Ok how is she going to pay this' … what insurance?"
>
> "@20:11 — Bart 'Her name is not there'. @20:14 — Mom 'how come it is there now'? @20:15 — Bart 'It's not, it's not, it's with the company'."
>
> "@21:03 — Bart '… if something will show that she is taking the money, I have an obligation to stop it. Right. I will not tolerate anything that'll be illegal… there is nothing that is been put together that'll show her as having a personal interest in this money at all.'"
>
> "Raffi had a policy on his life that was owned by his [corporation]… the corporation is the beneficiary… Everything has been received in trust, and put in an account that is showing to be in trust for Ashton or its in the company."
>
> "@25:21 — Bart 'How do we prove it, without Darrell acknowledging it? If Darrell gives us something that says that out of the x amount of dollars... I know what came in cuz i closed the deal'."

Establishes: the lawyer's own account of the money as corporate and held in trust for Ashton; that he states he closed the real-estate transaction in which Raffi and Darrell Lauzon bought the property. **Does not establish:** the reason the deposit went to the corporate account; what happened after 32:10 of the recording.

E-14 · written account · Julie Triferis

Document: `1000087934.jpg.txt` — the witness's own written account. **Status:** OCR only; a witness attestation, not a corroborated fact.

> "With Betty's permission I told her I was going to voice record our entire meeting with Bart. And I did so!"
>
> "On or about Augest 2016 Bart Seguin then showed up to Raffi's house and watched me load my stuff into a truck and when I was finished he had me surrender my house keys to him… Raffi's computer was inside his house and left on the kitchen counter."
>
> "…I was then told by Bart Seguin during [a meeting with] Lucy Ceylan in his office… that Ivana has the computer, that I was correct, Bart took it from Raffi's house the day I moved out and while he locked it up!!!"

Establishes: that a named witness makes this claim in writing. **Does not establish:** that it is true. No document in the corpus corroborates or contradicts it, and no denial is held.

E-15 · 16 February 2017 · Notice of Objection and CV-17-25300

Status: NOT HELD. Not as an image, not as OCR. Requested from the Windsor courthouse; the Statement of Issues for CV-17-25300 was requested in the same letter and has not arrived.

The date is established twice, independently:

> Minutes of Settlement ¶5: "Betty filed a Notice of Objection, dated February 16, 2017 (the 'Objection'), objecting to Ivana attempting to eet [OCR: act] as estate trustee for the Estate, and commenced the Application in Court File No. CV-17-25300"
>
> Frank's court-records request: "...documents from the civil suit that was commenced [date] February 16, 2017 against Raffi's estranged wife, Ivana Hrvatin (aka Ivana Ceylan)."

Establishes: the date and the existence of the objection and the file number. **Does not establish:** its grounds, exhibits or signature — except as described by opposing counsel in E-16.

E-16 · 28 April 2017 · McTague Law Firm letter to Barton J. Seguin

Document: D. M. Sundin, McTague Law Firm LLP, our file 67863, to Barton J. Seguin, Shibley Righton LLP, WITHOUT PREJUDICE, "VIA EMAIL & HAND DELIVERY". **Held as:** full text, `20260118_184959.jpg.txt` (p.1) and `20260118_184953.jpg.txt` (p.2). **Status:** OCR, full text held.

> "We have now had the opportunity to discuss settlement with our client, Betty Ceylan, of the issues raised in the Notice of Objection filed by her in this matter. We enclose a copy of the Notice of Objection for ease of reference. Betty is willing to settle her dispute regarding **Ivana's authority to be either the beneficiary or the Trustee** of Raffi's Estate on the following terms:"
>
> "Failing a response from you within ten (10) days of the date of this letter, we have been instructed to commence an Application and to seek costs for same from Ivana."

Twelve terms, including: an Application on consent that Ivana "is specifically excluded from acting as Estate Trustee or taking as a beneficiary, pursuant to a Separation Agreement that specifically excludes her"; "an independent party to be agreed upon shall be appointed to act as Estate Trustee"; "Control of Raffi's social media accounts is to be surrendered to Lucy Ceylan"; all personal effects to the trustee; costs to the estate; supervised visitation; reimbursement to Darren Janke and to Crystal Rivard (~27 hours); return of the calligraphy pen and ink case, a camera, a painting and lumber. **Term 2 of the twelve falls across the page break and is missing from the record.**

Establishes: the Objection's ground, stated by opposing counsel in writing and never retracted; the twelve demands. **Does not establish:** term 2; the Objection's own text.

E-17 · 9 December 2017 · Minutes of Settlement

Document: four pages, between Bercuhi (Betty) Ceylan and Ivana Hrvatin, witnessed by David M. Sundin and Barton J. Seguin. **Held as:** OCR, `20260119_182134` (p.1), `_182129` (p.2), `_182124` (p.3), `_182118` (p.4). **Status:** OCR, full text held.

> "IN WITNESS WHEREOF, the Parties hereto have set their respective hands, as witnessed, as of the 9th day of December, 2017." [OCR: `9"`]
>
> "7. Betty shall forthwith withdraw the Objection;" "9. There shall be an Order … declaring that Ashton is the sole beneficiary of the Estate and that a trust for Ashton be set up in accordance with paragraph 4(c) of the Last Will and Testament of Raffi, dated November 11, 2007 (the 'Trust')…" "10. … (i) Ivana shall be the Trustee of the Trust; (ii) Ivana shall not take any compensation…; (iii) Ivana shall provide a financial update on an annual basis to Betty… and to the Office of the Children's Lawyer; (iv) … by on or before March 31, 2019, and each year thereafter." "13. The Estate shall make payment to Betty of the all-inclusive sum of $60,000.00, on account of Betty's Claim for recovery of certain loans she made to Raffi and on account of costs for the Application;" "14. Within thirty days, Ivana shall cause Raffi's Facebook page to be shut down;" "15. … Ivana shall, at the expense of the Estate, install a tombstone at Raffi's grave … 'Beloved Son, Brother, and Father';" "16. … Should the lithograph be valued at more than $500.00, it shall be turned over to Ivana, who shall preserve it for Ashton;" "17. Ivana shall release a certain calligraphy set to Betty forthwith…" "22. … they shall indicate only that the 'litigation has been discontinued', and shall give no further or other indication of the outcome;"

Establishes: what was actually agreed; the settlement sum; the trust and its reporting obligations; that Ivana remained trustee. **Does not establish:** why the exclusion and the independent trustee disappeared from the demands; whether any of ¶11–¶17 was performed.

E-18 · December 2017 · Form 74.4 and the Certificate of Appointment

Document: Application for Certificate of Appointment of Estate Trustee with a Will (Form 74.4), sworn December 2017 (day illegible in OCR); Certificate of Appointment sealed 2017 (day and month illegible). **Held as:** OCR, `1000087595.jpg.txt`, `20260106_111522.jpg.txt`, `20260106_111441.jpg.txt`. **Status:** OCR only.

> "VALUE OF ASSETS OF ESTATE — Personal Property $27,600.00 · Real estate, net of encumbrances $80,514.00 · **Total $108,114.00**"
>
> "CERTIFICATE OF APPOINTMENT OF ESTATE TRUSTEE WITH A WILL — Applicant: Ivana Ceylan — 219 Branton Crescent, Tecumseh, ON N9K 1G1 — Water Quality Technician"
>
> Backsheet: "BARTON J. SEGUIN / SHIBLEY RIGHTON LLP … LSUC #46519C / Lawyers for the Applicant(s) / File #2161768"

Establishes: the estate value sworn to the court; the identity of the trustee appointed; counsel of record; that the will attached is the one of 11 November 2007. **Does not establish:** the exact signature date; the estate file number (trailing character illegible in OCR); any component attribution within the $108,114.00.

E-19 · 11 November 2007 · The will that was probated

Document: Last Will and Testament of Raffi Ceylan, executed 11 November 2007; 12-page signed copy. **Held as:** OCR of the pages, `lucy_ocr_out/…Ceylan-1.pdf_pg_*.txt`. The PDF itself is not readable by this session. **Status:** OCR only. Executed page reads "subscribed my name this 11th November, 2[0]0[7]".

Terms: ¶2 nominates his wife as estate trustee. ¶4(b) gives the residue to his wife if she survives him 30 days. ¶4(c) makes provision for the children by trust. ¶5–6 express the children's entitlement at age 25. ¶9 appoints "my sister-in-law, ELENA O'NEILL" as substitute decision-maker for the minors, then "my mother-in-law, LYDIA ANNA HRVATIN". **¶3 of this will is struck by the 13 March 2018 order and no readable copy of ¶3 exists on this box.**

E-20 · 13 March 2018 · Order on consent (Howard J.)

Document: Ontario Superior Court of Justice, Windsor; "TUESDAY, THE 13th DAY OF MARCH, 2018"; heard on the consent of the parties. **Held as:** OCR, `1000089660.jpg.txt`, `1000085857.jpg.txt`, `image004.jpg.txt`. **Status:** OCR, two independent copies read.

> "1. THIS COURT ORDERS AND DECLARES that Ashton Ceylan is the sole beneficiary of the Estate of Raffi Ceylan…"
>
> "2. THIS COURT ORDERS that the Estate shall be administered without reference to paragraphs 3 and 4(b) of the Last Will and Testament of Raffi Ceylan, dated November 11, 2007 (the 'Will'), which shall hereby be of no force or effect, and that any sums to which Ashton Ceylan is entitled as the residual beneficiary of the Estate shall be administered in accordance with the trust provisions set out in paragraph 4(c) of the Will… (i) Ivana Hrvatin shall be the Trustee of the Trust…"
>
> "3. THIS COURT ORDERS that the balance of the Application is dismissed with prejudice and without costs."

Establishes: that two paragraphs of a will probated four months earlier were declared of no force or effect by consent; that the residue was redirected to the child's trust; that Ivana remained trustee. **Does not establish:** what ¶3 of the will contained; the motion record filed as consent.

E-21 · February 2018 · Full and Final Mutual Release

Document: "BERCUHI CEYLAN, also known as BETTY CEYLAN … Applicant and IVANA CEYLAN, also known as IVANA HRVATIN, and ELENA O'NEILL … Respondents — FULL AND FINAL MUTUAL RELEASE". Day blank; month February 2018. **Held as:** OCR, `1000088799.jpg.txt`, `20260120_080925.jpg.txt`.

> "(iii) Lucy, who is a non-party, being bound by the terms of this Full and Final Mutual Release;" "(iv) A dismissal of the Application in Court File No. CV-17-25300 on a with prejudice and without costs basis;"

Establishes: that a person who was never a party to CV-17-25300 is inside the mutual release; the consideration. **Does not establish:** the day of execution; Lucy Ceylan's consent to being bound (¶20 of the Minutes has Betty cause her to sign; no signed copy by Lucy is held).

E-22 · 5 December 2017 · Mediation Brief of the Applicant (167 pages)

Document: Mediation Brief of the Applicant in CV-17-25300, dated 5 December 2017, 167 pages. **Held as:** OCR recovered from a single JPEG (`1000090238.jpg`) plus the node addendum `NODE-06-ADDENDUM-MEDIATION-BRIEF.md`. **Status:** OCR held; the 167 pages were found inside one image file.

> "The total amount owing on the loans to Betty total the sum of $58,512.16." (plain reading of the brief's OCR text) “Kindly confirm that the Estate will pay the outstanding sum of $58,512.16 to Betty.”

The $60,000 payment in ¶13 of the Minutes exceeds that claim by **$1,487.84** (60,000.00 − 58,512.16) — arithmetic on the two figures, not a costs figure quoted from a document.

Establishes: the applicant's pleaded case at length, and the sizes of the two money claims. **Does not establish:** the respondent's answer (not held).

E-23 · 3 October 2017 · The procedural order the settlement short-circuited

Document: Order of Howard J., on consent; `20260119_180106.jpg.txt`.

> "3. The Parties are to schedule a Mediation session by on or before October 27, 2017, with the Mediation session to be held by on or before December 1, 2017 …"
> "… Factums and Brief of Authorities by on or before March 9, 2018."

Establishes: the court-ordered timetable — mediation by 1 December 2017, hearing set for 19 March 2018. The Minutes are dated 9 December 2017, eight days after the mediation deadline, and the consent order came 13 March 2018, six days before the hearing was due.

E-24 · correspondence · The courthouse on the separation agreement

Document: registrar's correspondence, `Screenshot_20260128_120722_Gallery.jpg.txt`.

> "the Certificate of Appointment of Estate Trustee, Application Form for Estate Trustee, last known will, as well as the entire contents of civil file CV-17-25300" "The Separation Agreement was never filed with us."

Establishes: that the separation agreement — the instrument the April 2017 position relied on to exclude Ivana — was never filed with the court, in the courthouse's own words.

E-25 · 13 November 2026 · Office of the Inspector General of Policing, Decision 26-1234

Document: Decision 26-1234, Office of the Inspector General. **Secondary** — a decision, not a primary record.

> "2016, under unexplained circumstances), control of Northern Exposure Decks and Fences Ltd. was transferred on paper." "The Filing Discrepancy: The corporate registry records the 'Person Authorizing Filing' (PAF) for this change as Barton J. Seguin, explicitly classified by the system as 'OTHER' holding no official office or directorship in the company." "Financial Outcome: This filing placed corporate control and a subsequent $607,228.70 in life insurance proceeds (under a Sun Life policy) under the sole control of Ivana Hrvatin, a non-officer who previously held no recorded position in the company."

Establishes: that an Ontario oversight body adopted the registry facts in writing on 13 November 2026. **Does not establish:** the conclusion that the money reached Ivana Hrvatin personally — the bank document in E-11 shows it entering the corporation's account and no document here shows it reaching her.

E-26 · 13 November 2026 · The canary token geography ledger

Document: page pull of every fired campaign token from the token service's own per-token history API, 13 November 2026 15:54 EST; reconciliation against the mailbox sweep; per-house geography. **Held as:** `/home/atlas/CANARY-EVAL-2026-11-13/deliver3/token-geography-summary.md` with `token-geography-ledger.csv` (1,328 tokens), `token-geography-tokens.csv`, `token-geography-delta.csv` (191 rows) and `_numbers.json`. **Status:** machine-generated from the service's API; every figure on this page is read from those files.

```
campaign tokens fired          1,328
firing rows (page pull)        3,421
firing rows (mailbox sweep)    2,531   undercounts by 890 (+35.2%)
distinct source addresses        571
distinct rendered cities         125
first firing (EST)      2026-02-16 00:28:49
last firing  (EST)      2026-11-13 15:34:42
```

house the instrument was addressed to	firings	tokens that fired	distinct egresses	cities	dominant city / ASN
Legislature / MPs	872	402	19	6	Toronto (863) / Microsoft
UNMAPPED	732	386	225	68	Toronto (360) / Microsoft
Municipal	579	238	214	55	Toronto (217) / Microsoft
Sun Life	267	35	21	4	Toronto (126) / Netskope
Newsroom	165	31	88	36	Toronto (73) / Google
PMO	114	33	31	4	Toronto (84) / Google
Ombudsman	100	8	24	8	Toronto (68) / Bell Canada
Broadcast / shared	95	23	66	28	Toronto (32) / Microsoft
Police (other)	86	15	24	6	London, ON (35) / LARG*net
Windsor Police	71	10	13	5	Windsor (58) / CW-E
IG	69	33	31	13	Toronto (48) / Microsoft
Attorney General	62	37	21	3	Toronto (58) / Microsoft
Solicitor General	46	17	16	2	Toronto (42) / Microsoft
FSRA	32	9	13	3	Toronto (19) / Bell Canada
SIU	32	8	15	4	Toronto (19) / Google
OPP	29	14	14	5	Toronto (22) / Microsoft
PCO	25	13	9	2	Toronto (14) / Microsoft
TD	22	11	10	7	Lappeenranta, FI (4) / Microsoft
CIBC	18	1	5	3	Toronto (12) / Google
OCC	5	4	4	1	Toronto (5) / Microsoft

Establishes: that 1,328 uniquely-tokened instruments were opened 3,421 times, from 571 source addresses rendering to 125 cities, between 16 February and 13 November 2026; and the per-house distribution of those openings, including 71 openings on the Windsor Police instrument. **Does not establish:** who sat at each address. Attribution past the egress is a separate question, not answered here and not asserted in Part I. **Note on the limits:** eight tokens sit on the service's 50-row page cap, so 50 is a floor rather than a count for those; the sweep figure is retained for them, and the one inverse case is kept in the delta file rather than hidden.

ANNEX GAPS — named, not filled

#	Document named in the record	Status
G-01	Sun Life transfer-of-ownership form, unredacted	NOT HELD — undertaking unperformed
G-02	Instrument behind the 30 Sep 2016 Notice of Change	NOT HELD
G-03	Share register / share certificates / any share transfer	NOT HELD
G-04	TD statement run from 1 Oct 2016 forward; TD Direct Investing 77H225	NOT HELD
G-05	Notice of Objection 16 Feb 2017; Statement of Issues, CV-17-25300	NOT HELD — requested from courthouse
G-06	The estate file (2017 EG …): inventory, accounts, receipts, endorsement	NOT HELD
G-07	Estate administration accounts; trust deed; trust account; CRA trust number	NOT HELD
G-08	Annual financial updates due 31 Mar 2019 and each year after	NOT HELD
G-09	Receipt/cheque proving the $60,000 was paid and from what account	NOT HELD
G-10	Compliance documents: ¶11–¶17 (tombstone, Facebook, lithograph, calligraphy)	NOT HELD
G-11	Audio of the 16 Nov 2016 meeting (Exhibit 19), complete	NOT HELD — fragment only
G-12	EMS run report, dispatch log, OPP post-mortem photographs, scene DVD	NOT HELD
G-13	Chapleau Health Services emergency room record	NOT HELD
G-14	§14/§15 form 3 pages at full resolution: signature and date fields	NOT HELD in readable form
G-15	Mediation Brief respondent's answer; motion record filed as consent	NOT HELD
G-16	Withdrawal of the Notice of Objection	NOT HELD
G-17	Any document dated December 2016	Searched; none exists in the readable corpus
G-18	Dave Simetic record (SIMETIC FULL SWEEP deliverable)	NOT BUILT
G-19	Built chain for Frank's own case, to the standard of Nodes 01–06	NOT BUILT
G-20	Wallis v3 package contents	NOT ON THIS BOX